Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

Opinion
Video

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.